The reimbursement listing process for ‘Vyndamax,’ Pfizer’s treatment for transthyretin amyloid cardiomyopathy (ATTR-CM), is gaining attention in Korea.

According to industry sources, discussions for the reimbursement of Pfizer Korea’s Vyndamax (tafamidis 61mg) for Transthyretin amyloid cardiomyopathy (ATTR-CM) have again begun.

Once again, the key players will be the Pharmacoconomic Evaluation Subcommittee and the Reimbursement Standard Subcommittee. Vyndamax failed its first reimbursement attempt in early 2021. The company then made its second attempt in the first half of the same year after conducting a pharmacoeconomic evaluation and preparing a risk-sharing agreement (RSA) b